Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credit: AI
Doctors may soon be able to determine a brain tumour’s type right during the surgery. Doctors remove a tissue sample during surgery to analyse the tumour. Patients undergoing surgery for brain tumour may not have to wait days or weeks to find out.
A new rapid genetic test being tested by the NHS in England promises to shorten the wait time drastically. The technology can find the precise type of brain tumour within about two hours, while the patient is still on the operating table.
Developed by researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust, the test analyses the genetic code of a tumour sample rather than relying only on traditional microscopic examination.
Brain tumours are not connected to one single disease. There are more than 100 types, ranging from relatively slow-growing tumours to highly aggressive cancers. Knowing the exact type and characteristics of a tumour is important because treatment courses can differ significantly.
Traditionally, doctors take a sample during surgery and send it to a pathology laboratory. The tissue sample is then examined under a microscope. Finding out the tumour type usually takes weeks.
According to an NHS centre, the current average time for a brain tumour diagnosis can be around 26 days, while other reports have estimated up to almost eight weeks in some cases. In case of aggressive tumours, waiting period can be particularly difficult and longer.
The rapid genomic test works by analysing a small piece of the tumour which is taken during the surgery and sent to the laboratory, where its DNA is analysed using a shoebox-sized sequencing machine developed by Oxford Nanopore.
Inside the machine, DNA molecules pass through tiny pores. As they move through, the system reads their genetic information and uses the resulting genomic pattern to identify the tumour type.
Marking a significant jump in speed and time taken, the test can help doctors can receive detailed diagnosis during the operation itself instead of weeks.
Also read: Radiotherapy Cuts Risk Of Atypical Meningioma Recurrence By Nearly Half: Lancet Study
Not only this test reduces weeks, sometimes months of anxiety, it can also help surgeons make immediate decisions about how much tumour tissue to remove while protecting healthy brain tissue.
Some tumour types require different surgical approaches, and having molecular information immediately could help the surgeon take quick decisions.
A rapid diagnosis can also help patients to begin the appropriate treatment sooner and gain earlier access to clinical trials designed for specific tumour types.
The NHS is piloting the technology to determine how well rapid genomic testing works in routine clinical practice. The initial rollout covers five specialist centres, including Nottingham University Hospitals, University Hospitals Birmingham, Great Ormond Street Hospital, King's College Hospital and Newcastle Hospitals. More centres are expected to be added soon.
The rapid testing is therefore intended to complement the entire diagnostic process rather than make traditional pathology obsolete. If the NHS pilot is successful, rapid genomic testing could eventually make that information available much earlier to brain tumour patients across England.
Credit: AI
The early signs of type 2 diabetes could be related to your gut. They may signal a warning risk long before you take a blood sugar test.
New research suggests that changes in the trillions of bacteria living in the gut may accurately predict future diabetes risk.
An analysis of microbiome data from more than 229,000 adults in the UK and US identified hundreds of bacterial changes linked with type 2 diabetes, including changes that appeared before measurable abnormalities in blood glucose.
The findings are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan.
Researchers from the University of Trento in Italy and collaborators in the UK analysed metagenomic data, which involves examining the DNA of microorganisms living in the gut.
The study included 229,025 people, of whom 3,627 had type 2 diabetes, 14,022 had prediabetes and 211,376 had normal blood glucose levels. The average age was 50, and about 74% of participants were women.
After accounting for factors including age, sex and body mass index, researchers identified 789 bacterial species associated with type 2 diabetes.
Of these, 168 were found at higher levels in people with diabetes, while 621 were present at lower levels.
One example was Enterocloster bolteae, which was more abundant in people with type 2 diabetes. In contrast, Romboutsia timonensis was found at lower levels.
Interestingly, 587 of the 789 bacterial species were also associated with unmedicated prediabetes, suggesting that some of these microbial changes may occur before diabetes is diagnosed.
Also read: Diabetes Linked To 55% Risk Of Kidney Disease, Heart Failure Or Death Within 10 Years: Study
The researchers looked at 135,093 people who had normal blood glucose and did not have diabetes or prediabetes. They also had information about how their blood sugar responded after eating.
Normally, blood glucose rises after a meal and then falls. If it remains elevated for longer than expected, it can indicate that the body's muscles are not responding properly to insulin, an early feature of insulin resistance.
Researchers found that people whose blood sugar remained elevated for longer were more likely to have the gut bacterial pattern linked with type 2 diabetes. The microbiome changes became more pronounced as insulin resistance increased.
Therefore, it was observed that the gut microbiome carried clues about metabolic problems even when standard blood glucose levels were still normal.
Also read: Muscle Loss In Middle Age May Signal Dementia Risk, Study Finds
Currently, diabetes and prediabetes are diagnosed using tests like HbA1c, fasting blood glucose and oral glucose tolerance tests.
For people who have normal results, doctors generally assess future diabetes risk using factors like age, sex, body mass index and family history. A gut microbiome test is not currently part of routine diabetes screening.
The researchers believe microbiome analysis could eventually provide an additional layer of risk assessment, identifying people who could benefit from earlier lifestyle interventions.
Professor Tim Spector, one of the study's authors, Scientific Co-Founder, ZOE, said, “These latest findings represent a major step forward in understanding how our gut microbiome is linked directly with metabolic disease. Identifying these clear microbial changes before blood sugar levels worsen could lead to earlier intervention with food and lifestyle choices, as well as treatment options, to prevent T2D."
The researchers say that microbiome analysis should not replace existing tests for diabetes or prediabetes. The current findings show associations between particular bacterial patterns and diabetes risk.
The researchers also found that some of the bacteria making up the diabetes-related signature have never been isolated or cultivated in a laboratory and are new in terms of scientific investigation.
Additional research will be needed to assess whether these microbial changes can reliably predict who will develop diabetes and whether changing the microbiome can actually reduce that risk.
Credit: iStock
A Type 2 diabetes diagnosis increases the risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, by 55% within 10 years, according to analysis of data from more than 1.6 million patients across the US.
Within the first five years of a Type 2 diabetes diagnosis, the study found that the combined risk of developing CKD or heart failure, or dying, was 33% on average. By year 10, that combined risk rises to 55%.
The study shows within five years of a first diabetes diagnosis, the risk of developing CKD first was more than twice that of developing heart failure first (19.0% vs. 8.3%).
However, among people who developed heart failure first, there was a 42% risk of developing CKD within the following five years.
Conversely, among those who developed CKD first, there was a 23% risk of developing heart failure within the following five years.
"Our findings clearly show how the serious complications associated with type 2 diabetes rise sharply over time as the common combination of obesity, abnormal blood fats, high blood pressure and higher blood sugar damages blood vessels and vital organs," said Professor Naveed Sattar of the University of Glasgow in Scotland, UK.
Type 2 diabetes is projected to become the world's most prevalent epidemic disease, affecting an estimated 1.3 billion people by 2050.
It frequently occurs alongside obesity, high blood pressure, heart failure, CKD and depression, contributing substantially to the global burden of multi-morbidity.
The researchers say the findings highlight the importance of early, proactive and holistic management of Type 2 diabetes to help reduce the risk of serious complications.
"Our results emphasize the critical importance of detecting and treating type 2 diabetes thoroughly at the earliest opportunity to help reduce the risk of serious complications," Sattar added.
The team included 1,617,508 patients newly diagnosed with diabetes between January 1, 2010, and March 31, 2024, from across the US.
The average age of participants at enrollment was 59, and 51% were female. Among the 13% of patients who had a body mass index (BMI) recorded, the median was 30.9 kg/m².
Almost three-quarters (72%) of participants were living with dyslipidemia, or high levels of cholesterol and other fats in the blood, while more than two-thirds (68%) had high blood pressure.
The US Centers for Disease Control and Prevention (CDC) explains that diabetes, CKD and heart disease are interconnected.
High blood sugar can gradually damage the kidneys, reducing their ability to filter blood and potentially leading to CKD. When kidney function declines, it can also put additional stress on the heart.
Common Risk Factors
Risk factors that can overlap across diabetes, CKD and heart disease include:
The CDC recommends lifestyle measures that can help reduce the risk of these conditions and their complications:
© $2026 Times Horizon Private Limited